Royal LePage bumps up home price forecast for this year as momentum builds

Exness, one of the world’s largest multi-asset brokers, proudly welcomes Arab trader, educator, and author Hussain Almatrouk to Exness Team Pro, the global network of elite traders and mentors who embody trading excellence and a strong sense of integrity. A veteran trader, active since 2009, Hussain Almatrouk brings a distinctive perspective shaped by years of…

Earlier in 2026, the BoC flagged a two-sided risk profile: the possibility of rate cuts if growth disappointed more sharply than forecast, and potential hikes if energy prices from the Iran conflict drove a sustained, generalized consumer price shock. In recent weeks, neither scenario has materialized. Inflation concerns retreat Higher oil prices stemming from restricted…

NEW ORLEANS, July 10, 2026 /PRNewswire/ — ClaimsFiler, a FREE shareholder information service, reminds investors that they have until August 3, 2026 to file lead plaintiff applications in a securities class action lawsuit against GeneDx Holdings Corp. (NasdaqGS: WGS), if they purchased or otherwise acquired the Company’s shares between April 16, 2025 and May 4,…

Key Points Tesla is the EV leader and is looking to tap into several transformational opportunities. Rivian could ride a strong tailwind from a new model launch and its efforts to achieve self-driving capabilities. One of these stocks looks much more attractive than the other. These 10 stocks could mint the next wave of millionaires…

Dr Douglas Williams is a veteran senior executive and board member for several biotech companies. During his time at Biogen, ZymoGenetics, Amgen Immunex and Seattle Genetics, he was involved in the development of several multibillion-dollar treatments, including Enbrel, Tecfidera and Spinraza. Matthew Partridge: The time and cost of clinical trials has been seen as one…